McVerry B A, Auger M, Bellingham A J
Br J Haematol. 1985 Sep;61(1):145-8. doi: 10.1111/j.1365-2141.1985.tb04070.x.
Danazol has recently been reported to be an effective mode of treatment for patients with refractory immune thrombocytopenic purpura. Following a 3 month trial of danazol, only one of 10 patients experienced a sustained increase in platelet counts and two other patients had a transient improvement. While the drug was well tolerated, it does not appear to be particularly helpful in the management of these patients.
据报道，达那唑是治疗难治性免疫性血小板减少性紫癜患者的一种有效治疗方式。在对达那唑进行3个月的试验后，10名患者中只有1名患者的血小板计数持续增加，另外2名患者有短暂改善。虽然该药物耐受性良好，但在这些患者的治疗中似乎并不是特别有用。
